Table 1.

Association of MAGE‐A and NY‐ESO‐1 expression with histopathological parameters in breast cancer

MAGE‐A staining:	n			% of cases		P‐value	NY‐ESO‐1 staining:	n			% of cases		P‐valuea
	Total	MAGE‐A‐positive	MAGE‐A‐negative	Negative	Positive			Total	NY‐ESO‐1‐positive	NY‐ESO‐negative	Negative	Positive
Age (years)							Age (years)
>40	273	237	36	87	13	NS	>40	300	287	13	96	4	NS
≤40	35	27	8	77	23		≤40	38	38	0	100	0
n	308						n	338
Grade							Grade
G1	46	46	0	100	0	<0.0001	G1	50	50	0	100	0	0.023
G2	176	157	19	89	11		G2	170	166	4	98	2
G3	140	106	34	76	24		G3	134	124	10	93	7
n	362						n	354
Mitotic score							Mitotic score
1	43	43	0	100	0	<0.0001	1	199	196	3	98	2	0.0255
2	154	137	17	89	11		2	47	44	3	94	6
3	126	95	31	75	25		3	107	99	8	93	7
n	323						n	353
Histological type							Histological type
Ductal NOS	188	161	27	86	14	NS	Ductal NOS	207	198	9	96	4	NS
Lobular/variants	37	35	2	95	5		Lobular/variants	42	42	0	100	0
Mixed ductolobular	30	26	4	87	13		Mixed ductolobular	32	31	1	97	3
Mixed	30	25	5	83	17		Mixed ductolobular	31	28	3	90	10
Metaplastic	14	9	5	64	36		Metaplastic	15	15	0	100	0
Special types	24	20	4	83	17		Special types	27	26	1	96	4
n	323						n	354
Lymph node status							Lymph node status
Negative	97	84	13	87	13	NS	Negative	102	100	2	98	2	NS
Positive	82	69	13	84	16		Positive	88	83	5	94	6
n	179						n	190
Tumour size (mm)							Tumour size (mm)
< 20	140	125	15	89	11	NS	<20	152	147	5	97	3	NS
20–50	121	98	23	81	19		20–50	132	127	5	96	4
>50	21	18	3	86	14		>50	22	20	2	91	9
n	282						n	306
Lymphovascular invasion							Lymphovascular invasion
Absent	236	202	34	86	14	NS	Absent	262	252	10	96	4	NS
Present	87	73	14	84	16		Present	92	88	4	96	4
n	323						n	354
Lymphocytic infiltrate							Lymphocytic infiltrate
Absent	108	105	3	97	3	<0.0001	Absent	123	123	0	100	0	NS
Mild	145	117	28	81	19		Mild	157	150	7	96	4
Moderate‐severe	57	42	15	74	26		Moderate‐severe	61	55	6	90	10
n	310						n	341
Central scarring/fibrosis							Central scarring/fibrosis
Absent	289	248	41	86	14	NS	Absent	319	306	13	96	4	NS
Present	34	27	7	79	21		Present	35	34	1	97	3
n	323							n	354
Tumour border							Tumour border
Infiltrative	281	247	34	88	12	0.0023	infiltrative	310	299	11	96	4	NS
Pushing	45	31	14	69	31		Pushing	44	41	3	93	7
n	326						n	354
HR status							Hormone receptor (HR) status
Negative	77	46	31	59.7	40.3	<0.0001	Negative	68	66	2	97.1	2.9	<0.0001
Positive	244	227	17	93.0	7.0		Positive	282	270	12	95.7	4.3
n	321						n	350
ER status							ER status
Positive	241	225	16	93	7	<0.0001	Positive	270	268	2	99	1	<0.0001
Negative	83	51	32	61	39		Negative	85	73	12	86	14
n	324						n	355
HER2 status (CISH)							HER2 status (CISH)
Negative	286	244	42	85	15	NS	Negative	314	301	13	96	4	ns
Positive	30	27	3	90	10		Positive	31	31	0	100	0
n	316						n	345
Ki67							Ki67
Negative	192	177	15	92	8	<0.0001	Negative	192	188	4	98	2	0.0386
Positive	124	93	31	75	25		Positive	124	115	9	93	7
n	316						n	316
Basal marker: CK14, CK5, EGFR							Basal marker: CK14, CK5. EGFR
Negative	216	199	17	92	8	<0.0001	Negative	236	235	1	100	0	<0.0001
Positive	87	58	29	67	33		Positive	91	78	13	86	14
n	303						n	327
Vimentin							Vimentin
Negative	284	253	31	89	11	<0.0001	Negative	316	308	8	97	3	0.0016
Positive	38	21	17	55	45		Positive	38	32	6	84	16
n	322						n	354
Androgen receptor							Androgen receptor
Negative	35	19	16	54	46	<0.0001	Negative	38	30	8	79	21	<0.0001
Positive	278	248	30	89	11		Positive	305	300	5	98	2
n	313						n	343

CISH, chromogenic in‐situ hybridisation; CK, cytokeratin; EGFR, epidermal growth factor receptor; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; MAGE, melanoma‐associated antigen; NOS, not otherwise specified; NS, not significant; NY‐ESO‐1, New York Esophageal Squamous Cell Carcinoma‐1. st.

^aChi‐square test or Fisher's exact test.